Abstract Library

#4660 Clinical significance of interval imaging in patients with well-differentiated neuroendocrine neoplasms (NENs) receiving peptide receptor radionuclide therapy (PRRT)

Introduction: PRRT is an effective therapy for advanced NENs with SSTR-avid disease, however, the role of interval imaging in between PRRT cycles and its benefit is unknown.

Conference:

Presenting Author:

Authors: Grewal U, Patel R, Chandasekharan C,

Keywords: Peptide receptor radionuclide therapy, interval imaging, neuroendocrine tumour,

#4591 Efficacy of Trabectedin and Olaparib in homologous repair deficient neuroendocrine neoplasms – A subgroup analysis of the TOP-ART / PMO-1603 trial

Introduction: Genomic alterations resulting in homologous recombination deficiency (HRD) occur in a variety of cancers including neuroendocrine neoplasms (NEN). HRD-positive tumours are sensitive to PARP inhibitors such as olaparib. The DNA minor groove binder trabectedin leads to DNA double strand breaks and PARP activation. The combination of Trabectedin + Olaparib (TrO) may therefore have synergistic effects in HRD-positive tumours.

Conference:

Presenting Author: Apostolidis L

Authors: Apostolidis L, Ruebsam M, Teleanu M, Wagner S, Dorman K,

Keywords: Neuroendocrine Tumour, Neuroendocrine Carcinoma, targeted therapy, chemotherapy, HRD, olaparib, trabectedin, net, nec,

#4588 Spatial transcriptomics identifies Wnt signalling in multifocal ileal neuroendocrine tumours

Introduction: Ileal neuroendocrine tumours (i-NETs) often present with multiple primary tumours (>30-40%). Recent studies showed no shared somatic mutations in multiple primary tumours, highlighting the need to examine the tumour microenvironment in tumorigenesis. The Wnt signalling pathway is crucial for organ stem cell regulation. While the Wnt/β-catenin pathway influences prostate and pancreatic NET/Cs, its role in i-NETs remains unclear.

Conference:

Presenting Author:

Authors: Yogo A, Akanuma N, Kim G, Thirlwell C, Mäkinen N,

Keywords: Wnt Signalling, Spatial Transcriptomics,

#4584 Hepatic cytoreduction in advanced lung neuroendocrine neoplasms: A single institutional case series

Introduction: Role of hepatic cytoreductive surgery in well-differentiated gastroenteropancreatic neuroendocrine neoplasms (NENs) with liver metastases is well-described, however, its role in advanced lung NENs with liver metastases is unknown.

Conference:

Presenting Author: Grewal U

Authors: Grewal U, Patel R, Furqan M, Dillon J, Chandasekharan C,

Keywords: Lung neuroendocrine neoplasm, Hepatic cytoreductive surgery,

#4572 Steroid dosing to prevent tumour flare reaction with 177Lu-DOTATATE

Introduction: Tumour flare reactions including increased pain and small bowel obstruction (SBO) have been reported in patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) receiving 177Lu-DOTATATE. Retrospective reviews report tumour flare reactions in 6 to 40 percent of high-risk patients receiving 177Lu-DOTATATE and report success with using corticosteroid prophylaxis to prevent tumour flare recurrence with subsequent doses of 177Lu-DOTATATE (Strosberg, et al., 2021; Salner, et al., 2020).

Conference:

Presenting Author:

Authors: Cass A, Skotte E, Wheless M, Stockton S, Ramirez R,

Keywords: 177Lu-DOTATATE, corticosteroid prophylaxis, tumour flare,